	US 11,692,046 B2
	FGF21 mimetic antibodies and uses thereof
Regis Cebe, Saint-Louis (FR); Stephane Olland, Arlington, MA (US); and David Langdon Yowe, Belmont, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Dec. 18, 2020, as Appl. No. 17/127,600.
Application 17/127,600 is a division of application No. 15/890,302, filed on Feb. 6, 2018, granted, now 10,899,844.
Claims priority of provisional application 62/456,609, filed on Feb. 8, 2017.
Prior Publication US 2021/0171659 A1, Jun. 10, 2021
Int. Cl. C07K 16/40 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/40 (2013.01) [A61K 39/39591 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

13 Claims

1. A nucleic acid coding for an antibody or antigen-binding fragment thereof that binds to β-klotho comprising the nucleotide sequences encoding the heavy chain variable region as set forth in SEQ ID NOs: 16, 36, or 38; and the light chain variable region as set forth in SEQ ID Nos: 54, 27, 33, or 40.